Overview
Akeega is approved by the U.S. Food and Drug Administration (FDA) for the treatment of adults with metastatic castration-resistant prostate cancer (mCRPC) who have a BRCA mutation (a change in BRCA1 or BRCA2…

Overview
Camcevi ETM is approved by the U.S. Food and Drug Administration (FDA) for the treatment of adults with advanced prostate cancer. Camcevi ETM is also known by its drug name, leuprolide.

Leuprolide is a…

Overview
Camcevi Point-Lok Needle is approved by the U.S. Food and Drug Administration (FDA) for the treatment of adults with advanced prostate cancer. The prescription includes a prefilled syringe with a separate needle…

Overview
Camcevi SurGuard 3 Safety Needle is approved by the U.S. Food and Drug Administration (FDA) for the treatment of adults with advanced prostate cancer. The prescription includes a prefilled syringe called the…

Overview
Casodex is approved by the U.S. Food and Drug Administration (FDA) for the treatment of stage D2 metastatic prostate cancer. It is prescribed as part of combination therapy with a luteinizing hormone-releasing…

Overview
Eligard is approved by the U.S. Food and Drug Administration (FDA) for the treatment of advanced prostate cancer. It is a form of androgen deprivation therapy (ADT) that reduces testosterone levels to slow the…

Overview
Erleada is approved by the U.S. Food and Drug Administration (FDA) to treat metastatic castration-sensitive prostate cancer (mCSPC) and nonmetastatic castration-resistant prostate cancer (nmCSPC). When taking…

Overview
Firmagon is approved by the U.S. Food and Drug Administration (FDA) for the treatment of advanced prostate cancer. It is used as a form of androgen deprivation therapy (ADT) to reduce testosterone levels, which…

Overview
Lupron Depot is approved by the U.S. Food and Drug Administration (FDA) for the treatment of advanced prostate cancer. It is a form of androgen deprivation therapy (ADT) that helps lower testosterone levels…

Overview
Lynparza is approved by the U.S. Food and Drug Administration (FDA) for the treatment of adults with metastatic castration-resistant prostate cancer (mCRPC) that has either germline or somatic mutations…

Overview
Nilandron is approved by the U.S. Food and Drug Administration (FDA) for the treatment of metastatic (advanced) prostate cancer. It is prescribed for use in combination with surgical castration (removal of the…

Overview
Nubeqa is approved by the U.S. Food and Drug Administration (FDA) for the treatment of adult men with nonmetastatic castration-resistant prostate cancer (nmCRPC) and metastatic castration-sensitive prostate…

Overview
Orgovyx is approved by the U.S. Food and Drug Administration (FDA) for the treatment of advanced prostate cancer in adults. It is used as a form of androgen deprivation therapy (ADT) to reduce the levels of…

Overview
Pluvicto is approved by the U.S. Food and Drug Administration (FDA) for the treatment of adults with prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer (mCRPC) who…

Overview
Provenge is approved by the U.S. Food and Drug Administration (FDA) for the treatment of adults with metastatic castration-resistant prostate cancer (mCRPC) who have few or no symptoms. It is typically used in…

Overview
Rubraca is approved by the U.S. Food and Drug Administration (FDA) for the treatment of metastatic castration-resistant prostate cancer (mCRPC) in adults who have a BRCA gene mutation (change) and who have…

Overview
Talzenna is approved by the U.S. Food and Drug Administration (FDA) for the treatment of adults with metastatic (advanced) castration-resistant prostate cancer (mCRPC) that carries mutations (variations) in genes…

Overview
Trelstar is approved by the U.S. Food and Drug Administration (FDA) for the treatment of advanced prostate cancer. It is used as part of androgen deprivation therapy (ADT) to lower testosterone levels, which…

Overview
Xtandi is approved by the U.S. Food and Drug Administration (FDA) to treat several forms of prostate cancer, including castration-resistant prostate cancer (CRPC), metastatic castration-sensitive prostate cancer…

Overview
Zoladex is approved by the U.S. Food and Drug Administration (FDA) for the management of prostate cancer. It is specifically indicated for use in combination with flutamide for individuals with locally confined…

Overview
Zytiga is approved by the U.S. Food and Drug Administration (FDA) to treat prostate cancer. It is used in combination with prednisone to treat two types of advanced prostate cancer: metastatic (advanced)…